Yousif Capital Management LLC Decreases Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Yousif Capital Management LLC cut its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 7,709 shares of the medical instruments supplier’s stock after selling 169 shares during the period. Yousif Capital Management LLC’s holdings in LeMaitre Vascular were worth $647,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. NBC Securities Inc. purchased a new stake in LeMaitre Vascular during the first quarter valued at approximately $36,000. Smartleaf Asset Management LLC boosted its position in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its position in shares of LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 117 shares during the last quarter. Huntington National Bank boosted its position in shares of LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 455 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in LeMaitre Vascular during the fourth quarter valued at $150,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LMAT. Lake Street Capital increased their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Hold” and a consensus price target of $97.83.

LeMaitre Vascular Trading Up 0.1%

NASDAQ:LMAT opened at $81.78 on Friday. The firm has a market cap of $1.85 billion, a P/E ratio of 41.30, a PEG ratio of 2.16 and a beta of 0.83. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48. The stock’s 50 day simple moving average is $83.84 and its 200-day simple moving average is $89.62. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm had revenue of $59.87 million for the quarter, compared to analysts’ expectations of $57.61 million. During the same quarter in the previous year, the firm posted $0.44 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. Equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.40%.

Insider Activity

In related news, CEO George W. Lemaitre sold 18,733 shares of LeMaitre Vascular stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the sale, the chief executive officer now owns 1,873,651 shares of the company’s stock, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 100,000 shares of company stock worth $8,556,857. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.